Apremilast May Offer Cardiometabolic Benefit in Psoriasis Patients
5 to 6 percent decrease seen in subcutaneous and visceral adiposity at week 16 of treatment, which was maintained at 52 weeks
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.